Last updated: October 6, 2026
Prefest is a discontinued menopausal hormone therapy containing estradiol and norgestimate. Pfizer inherited the product through its acquisition of Pharmacia, but Prefest never became a material disclosed revenue driver. Its commercial decline reflects three forces: the post-2002 contraction in menopausal hormone therapy use, competition from lower-cost generic estrogen products, and the loss of differentiation for an oral fixed-dose combination.
What is Prefest and who marketed it?
Prefest is an oral hormone replacement therapy for postmenopausal symptoms. Each tablet contains:
| Product attribute |
Prefest |
| Active estrogen |
Estradiol, 1 mg |
| Progestin |
Norgestimate, 0.09 mg |
| Dosage form |
Oral tablet |
| Primary use |
Moderate-to-severe vasomotor symptoms and prevention of postmenopausal estrogen deficiency effects |
| Regulatory sponsor |
Pharmacia & Upjohn |
| Later corporate owner |
Pfizer |
| U.S. status |
Discontinued |
| Product type |
Fixed-dose estrogen-progestin combination |
Prefest used a 3-day cyclic regimen in which patients received estradiol alone for two days followed by estradiol plus norgestimate on the third day. The design sought to provide endometrial protection while limiting continuous progestin exposure.
The product was part of a broad menopausal hormone therapy market that included Prempro, Premarin, Activella, Angeliq, Estrace, Climara, Vivelle-Dot and generic estradiol products.
When did Prefest lose exclusivity and commercial relevance?
Prefest’s commercial decline occurred in stages rather than through a single patent event.
| Period |
Market event |
Commercial effect |
| Late 1990s |
FDA approval and launch |
Entry into oral menopausal hormone therapy |
| 2002 |
Women’s Health Initiative combined estrogen-progestin trial halted |
Broad reduction in physician and patient demand |
| 2003-2005 |
Greater scrutiny of systemic hormone therapy |
Lower prescription volume and weaker brand positioning |
| Mid-to-late 2000s |
Generic estrogen and alternative hormone products expanded |
Price and substitution pressure |
| Later period |
Pfizer portfolio rationalization and product discontinuation |
Prefest exited the U.S. commercial market |
| Current status |
No meaningful branded commercial presence |
Legacy product with limited market value |
The Women’s Health Initiative reported increased risks of coronary heart disease, stroke, pulmonary embolism and invasive breast cancer for the studied conjugated-estrogen-plus-medroxyprogesterone regimen. The trial did not test Prefest’s exact estradiol-norgestimate formulation, but the findings materially changed the treatment environment for systemic menopausal hormone therapy (Rossouw et al., 2002).
FDA later stated that menopausal hormone therapy should be used at the lowest effective dose for the shortest duration consistent with treatment goals. The agency’s position reduced the attractiveness of long-term systemic therapy and pressured older oral combination brands (U.S. Food and Drug Administration, 2022).
What is the FDA regulatory status of Prefest?
Prefest is not an actively marketed U.S. product. Public drug databases identify the product as discontinued. The discontinuation is generally treated as a commercial decision rather than an FDA safety withdrawal.
The regulatory position can be summarized as follows:
| Regulatory issue |
Status |
| Original NDA |
Approved in the United States |
| Current U.S. marketing |
Discontinued |
| FDA safety withdrawal |
No established withdrawal for safety reasons |
| Generic approval pathway |
Abbreviated New Drug Application, if a sponsor develops a pharmaceutically equivalent product |
| Current branded commercial strategy |
None publicly evident |
| Therapeutic category |
Systemic menopausal hormone therapy |
The distinction between “discontinued” and “withdrawn for safety or effectiveness” matters. A discontinued product can remain approved in a technical regulatory sense while no longer being supplied commercially. FDA’s Discontinued Drug Product List is not itself a finding that the drug was unsafe or ineffective.
What patents protected Prefest?
The public commercial value of Prefest was likely based on formulation and combination protection rather than a durable composition-of-matter patent around estradiol or norgestimate individually.
Estradiol has been used in pharmaceutical products for decades, and norgestimate also has an established prior-art history. A fixed combination can receive patent protection for:
- The specific estrogen-progestin combination.
- Cyclic dosing schedules.
- Methods for treating menopausal symptoms.
- Endometrial protection.
- Dosage forms and pharmaceutical compositions.
The available public record does not support assigning a current, enforceable Prefest patent estate without a claim-by-claim review of historical U.S. patent families, terminal disclaimers, maintenance-fee records and Orange Book listings. Prefest’s commercial discontinuation means that any remaining patent rights have limited practical market value unless a third party attempts to reintroduce an equivalent product.
What was the likely patent barrier?
The most important barriers were likely:
- Patent claims directed to the particular combination or regimen.
- FDA exclusivity associated with the original approval.
- Manufacturing know-how for consistent low-dose hormone tablets.
- Regulatory costs associated with demonstrating bioequivalence.
- Limited commercial demand after the hormone therapy market contracted.
The active ingredients themselves do not create a substantial modern barrier. Generic estradiol products are widely available, and the commercial rationale for reproducing the exact Prefest regimen is weak.
How many patents cover Prefest today?
No current, commercially meaningful Prefest patent estate can be established from publicly available product information alone. The relevant distinction is between historical patents that may once have supported the brand and live rights that could block present-day entry.
For a discontinued small-molecule product, an accurate patent assessment would require:
- The original NDA number and regulatory correspondence.
- Historical Orange Book entries.
- Patent listings submitted to FDA.
- Patent-family expiration analysis.
- Continuation and divisional records.
- Patent term adjustment and patent term extension calculations.
- Assignment and ownership records.
- Litigation and settlement history.
Without that reconstruction, a precise count of active Prefest patents would not be reliable. There is no clear evidence that an active Prefest-specific patent currently supports a material exclusivity position.
Did Prefest face Paragraph IV challenges?
No widely reported Paragraph IV litigation has become associated with Prefest in the way seen for high-revenue drugs. The absence of major public litigation is consistent with the product’s limited commercial opportunity.
A generic sponsor could have challenged listed patents through an ANDA Paragraph IV certification if relevant patents remained in the Orange Book. The economics would have been unfavorable, however, because:
- The market had already contracted.
- Estradiol alternatives were available.
- Physicians had shifted toward individualized therapy.
- Generic substitution reduced the value of a single-brand combination.
- The potential launch opportunity was much smaller than for major chronic medicines.
The absence of prominent litigation does not prove that no certification was ever filed. It indicates that Prefest did not generate a visible, high-value patent dispute comparable with leading branded products.
What formulations were protected by Prefest?
Prefest’s principal product differentiation was the oral fixed-dose combination and its cyclic administration schedule.
The formulation had several commercial limitations:
- It required systemic exposure to both estrogen and progestin.
- It did not offer the transdermal delivery advantages associated with patches and gels.
- It did not provide the broad dose flexibility of separate estrogen and progestin products.
- It was less adaptable for patients requiring individualized dose adjustments.
- It competed against products with stronger physician familiarity and broader distribution.
The formulation may have offered adherence advantages compared with separate products. That benefit was not sufficient to offset the market shift toward lower-dose, transdermal and individualized hormone therapy.
How did Prefest compare with competing hormone therapy products?
| Product |
Hormone regimen |
Delivery |
Competitive position |
| Prefest |
Estradiol plus norgestimate |
Oral |
Fixed-dose, cyclic combination; discontinued |
| Prempro |
Conjugated estrogens plus medroxyprogesterone acetate |
Oral |
Major legacy brand; directly affected by WHI |
| Activella |
Estradiol plus norethindrone acetate |
Oral |
Combination alternative with generic competition |
| Angeliq |
Estradiol plus drospirenone |
Oral |
Differentiated progestin but limited U.S. commercial scale |
| Estrace |
Estradiol |
Oral and vaginal products |
Strong estrogen brand with broad clinical familiarity |
| Vivelle-Dot |
Estradiol |
Transdermal patch |
Benefited from interest in lower systemic exposure and flexible dosing |
| Generic estradiol |
Estradiol |
Oral, vaginal and transdermal |
Low-cost substitute and major pricing pressure |
Prefest lacked a strong technical or commercial advantage over these alternatives. Its progestin, norgestimate, did not establish a large standalone menopause franchise, and the product did not control a delivery platform.
What market dynamics drove the financial decline?
The financial trajectory was negative after the early 2000s.
The Women’s Health Initiative changed prescribing behavior
The 2002 WHI announcement affected the entire systemic hormone therapy category. The study’s combined estrogen-progestin arm reported elevated risks of coronary heart disease, stroke, pulmonary embolism and breast cancer. Prescribing fell sharply across the category, including products that were not identical to the tested regimen.
Clinical practice later became more differentiated. Menopausal hormone therapy remained an option for selected patients, especially those with significant vasomotor symptoms, but the market shifted toward lower doses, shorter treatment durations and more individualized risk assessment (North American Menopause Society, 2022).
Generic competition reduced pricing power
Prefest competed against generic estrogen products and other combination therapies. Once physicians became less willing to prescribe systemic hormone therapy broadly, branded products had limited ability to sustain premium pricing.
The fixed-dose format also constrained commercial flexibility. Physicians could not independently adjust the estrogen and progestin components without changing products.
Pfizer did not disclose Prefest revenue
Pfizer’s public financial reporting aggregates products into large business segments and does not disclose standalone sales for Prefest. No reliable public revenue series exists for the brand.
| Financial metric |
Publicly available position |
| Annual Prefest revenue |
Not separately disclosed |
| Peak sales |
Not reliably reported |
| Current sales |
No meaningful U.S. branded revenue identified |
| Segment reporting |
Aggregated within broader Pfizer portfolios |
| Revenue exposure at Pfizer |
Immaterial relative to Pfizer’s major products |
| Residual value |
Primarily regulatory and historical, not commercial |
The absence of standalone revenue reporting is itself informative. Prefest was not large enough to influence Pfizer’s consolidated financial outlook or receive dedicated investor disclosure.
What generic launch risks exist for Prefest?
A generic launch would face limited patent risk but substantial market risk.
Regulatory risk
An ANDA sponsor would need to demonstrate pharmaceutical equivalence and bioequivalence for the relevant strengths and dosage regimen. Hormonal products require careful control of content uniformity, dissolution and assay performance.
Commercial risk
The main risk would be insufficient demand. A generic version could compete on price but would enter a market with:
- Low brand awareness.
- Multiple estrogen alternatives.
- Declining use of fixed-dose oral combinations.
- Preference for individualized regimens.
- Competition from transdermal products.
- Limited reimbursement advantage for an uncommon combination.
Manufacturing risk
The manufacturing process is technically manageable for an experienced oral-solid-dose manufacturer. The main barriers would involve low-dose content uniformity, stability, analytical validation and supply-chain economics rather than proprietary manufacturing technology.
Which companies could challenge or replace Prefest?
The relevant competitive set includes generic manufacturers of estradiol products and companies marketing menopausal hormone therapies, including:
- Teva Pharmaceuticals.
- Viatris.
- Amneal Pharmaceuticals.
- Prasco Laboratories.
- Noven Pharmaceuticals.
- Bayer, in markets where Angeliq is available.
- Pfizer, through its legacy hormone therapy portfolio.
These companies compete more effectively through separate estrogen products, transdermal systems or other combination products than through a direct Prefest replacement.
What is the litigation and settlement status?
No major, publicly prominent patent litigation or settlement agreement is associated with Prefest. The product did not generate the scale of patent disputes seen for major cardiovascular, oncology or biologic products.
The limited litigation profile reduces the likelihood that settlement agreements materially delayed generic entry. Prefest’s decline appears to have been driven by category economics and product discontinuation rather than an extended patent-enforcement campaign.
How strong is the Prefest patent estate?
The Prefest patent estate is commercially weak today.
| Patent-strength factor |
Assessment |
| Active ingredient protection |
Weak; ingredients are established |
| Fixed-combination protection |
Historically relevant, but likely expired or commercially inactive |
| Formulation protection |
Possible historical protection; limited current value |
| Method-of-use protection |
Potentially narrow and vulnerable to design-around |
| Regulatory exclusivity |
Expired |
| Generic substitution risk |
High |
| Re-launch attractiveness |
Low without a differentiated delivery or clinical profile |
The estate could still have historical importance for reconstructing Pfizer’s menopausal hormone therapy strategy. It does not appear to offer a meaningful current barrier to competitors.
Does Prefest have biosimilar risk?
No. Prefest is a conventional small-molecule drug, not a biologic. Biosimilar rules under the Biologics Price Competition and Innovation Act do not apply.
The relevant competitive threat is generic substitution through the ANDA pathway. That pathway is generally less complex and less costly than biosimilar development, although hormonal combination products still require careful bioequivalence work.
What is the geographic coverage of Prefest?
Prefest’s commercial importance was concentrated in the United States. Pfizer and its predecessor companies maintained broader international hormone therapy portfolios, but country-specific availability varied.
International exclusivity and market status cannot be inferred from U.S. discontinuation. Patent expiration, regulatory approval, reimbursement and commercialization differed by jurisdiction. The U.S. product’s exit is the clearest indicator of the brand’s financial trajectory because the U.S. was the largest and most commercially significant market.
Key Takeaways
- Prefest is an oral estradiol-norgestimate menopausal hormone therapy that has been discontinued in the United States.
- Pfizer inherited the product but did not report standalone Prefest revenue.
- The 2002 Women’s Health Initiative findings weakened the entire systemic hormone therapy market.
- Generic estrogen products, transdermal therapies and flexible combination strategies reduced Prefest’s commercial differentiation.
- No major public Paragraph IV litigation or settlement history is associated with the product.
- Prefest is a small-molecule drug and has no biosimilar exposure.
- Any historical formulation or method patents have limited present-day commercial value.
- A generic launch would face low patent risk but weak demand and unfavorable market economics.
- The product’s financial value is effectively residual rather than growth-oriented.
FAQs About Prefest Market Value and Exclusivity
Is Prefest still available by prescription?
No. Prefest is generally listed as discontinued in the U.S. market and is not a current branded commercial option.
Is there a generic version of Prefest?
There is no widely marketed generic product with the same commercial identity and regimen. Physicians can prescribe separate estradiol and progestin products, but those are not direct branded Prefest substitutes.
Was Prefest recalled?
There is no established evidence that Prefest was removed because of a product-specific safety recall. Its discontinuation is generally understood as a commercial and portfolio decision.
Did Pfizer disclose Prefest sales?
No. Pfizer did not separately report Prefest revenue in its public financial disclosures. Any sales were aggregated within broader pharmaceutical portfolio reporting.
Could Prefest be relaunched?
A relaunch would be technically possible if regulatory rights, manufacturing capability and market authorization remained available. The commercial case is weak unless a sponsor adds a differentiated delivery system, lower-dose strategy or new clinical positioning.
References
-
North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794.
-
Pfizer Inc. (2003-2023). Annual reports and Form 10-K filings. New York, NY: Author.
-
Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., Jackson, R. D., Beresford, S. A. A., Howard, B. V., Johnson, K. C., Kotchen, J. M., & Ockene, J. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA, 288(3), 321-333.
-
U.S. Food and Drug Administration. (2022). Menopausal hormone therapy information. Silver Spring, MD: U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. Silver Spring, MD: U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Discontinued drug product list. Silver Spring, MD: U.S. Department of Health and Human Services.
